Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 568 of 5804
-
Radiation zaps resistant cancer spots, may extend immunotherapy success
Disease control Recruiting nowThis Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing regimen with last dose of systemic therapy within 3 mo…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental antibody drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThe goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients. The main question it aims to answer is the rate of patients in complete response.
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo aims to wipe out hidden myeloma after transplant
Disease control Recruiting nowThe goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[ASCT\]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC…
Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can zapping tumors with surgery or radiation boost lung cancer treatment?
Disease control Recruiting nowUnfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases. The current standard of care therapy at this advanced stage of lung cancer includes systemic anti-c…
Phase: NA • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Esophageal cancer trial mixes chemo, radiation, and immunotherapy
Disease control OngoingThe goal of this clinical trial is to learn if immune microenvironment modification could improve the effect of chemoradiotherapy for patients with local advanced esophageal squamous cell carcinoma. The main questions it aims to answer are: 1. Does immune microenvironment could …
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to tame myeloma in seniors
Disease control Recruiting nowThe primary hypothesis of this study is that teclistamab SC in combination with daratumumab SC or lenalidomide will be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patients This is an open-label, multicenter, non-comparative, 2-cohort, 2-stag…
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 26, 2026 17:47 UTC
-
New drug shows promise for rare penile cancer
Disease control Recruiting nowThis phase II trial tests how well enfortumab vedotin works for treating patients with squamous cell carcinoma of the penis that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Enfortumab vedotin is a monoclonal antibody, enfort…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New eczema drug shows promise in Late-Stage trial
Disease control CompletedThis is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical pre…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for stomach cancer: drug cocktail shows promise in early trial
Disease control CompletedTo evaluate the safety and tolerability of the combination therapy of T-DXd, nivolumab, and chemotherapy in patients with untreated HER2-low gastric or gastroesophageal junction adenocarcinoma, and to determine the recommended dose. Subsequently, the efficacy and safety at the re…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for advanced breast cancer: drug combo enters human trials
Disease control Recruiting nowThis is a multicenter, open phase Ib/II clinical study, which is divided into two phases: dose exploration and efficacy expansion. Participants entering the study will receive HRS-8080 combined with Dalpiciclib Isethionate Tablets therapy.
Phase: PHASE1, PHASE2 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Lymph node surgery may boost cervical cancer treatment
Disease control Recruiting nowThis is an international, multicenter and randomized open-label phase III study designed to demonstrate, in patients with stage IIIC1 cervical cancer, whether para-aortic lymphadenectomy followed by tailored chemoradiation is associated with increased disease-free survival compar…
Phase: PHASE3 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant blood cancer
Disease control Recruiting nowThis is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to extend remission in aggressive lung cancer
Disease control Recruiting nowRAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of nir…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Hormone shots plus vaccine aims to supercharge immune attack on prostate cancer
Disease control Recruiting nowThis is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic ac…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a new pill protect kidneys from IgA nephropathy?
Disease control CompletedThe study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for lymphoma patients: drug combo trial launches
Disease control Recruiting nowEfficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Phase: PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:08 UTC
-
New drug linvoseltamab takes on multiple myeloma in early trial
Disease control Recruiting nowThis study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible)…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could stem cells help stroke patients recover? new trial begins
Disease control Recruiting nowThe primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to investigate the inflammatory response in a subclini…
Phase: PHASE2, PHASE3 • Sponsor: Cytopeutics Sdn. Bhd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New shot could help lower stubborn high cholesterol
Disease control CompletedA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Recombinant Fully Human Anti-PCSK9 Monoclonal Antibody Injection (SAL003) in Combination with Statin Therapy in Patients with Hypercholesterolemia and Mixed…
Phase: PHASE3 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New heart pump offers hope for advanced heart failure patients
Disease control Recruiting nowThe Icoms® FlowMaker® is a cardiac assist system in the true sense of the word. As assisting means to help or rescue, its function is providing assistance to the heart, which will continue to have its own hemodynamic pump function. The effect of the Icoms® FlowMaker® is to add an…
Phase: NA • Sponsor: FineHeart • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC